Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Amgen India investment totals $200 million through 2025
Advances Amgen's mission to serve patients with rare disease medicines
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Subscribe To Our Newsletter & Stay Updated
